Nuvaira’s Dennis Wahr Gives Presenting Tips, IDs his Role Models, Talks About Possibly Going Public

You’ll have a hard time finding a more modest man than Dennis Wahr, president and CEO of Nuvaira. But when asked what company he sees as being poised to establish the Interventional Pulmonology industry Wahr says Nuvaira might be the one. Nuvaira’s Targeted Lung Denervation, or TLD, is a non-surgical procedure that interrupts overactive nerve signals and may reduce obstructive airway symptoms, helping you to breathe easier. Could Nuvaira be the company to finally set the cement in the foundation of Interventional Pulmonology? Or will Nuvaira build upon the success of Pulmonx and Inspire, two other respiratory companies making great strides in commercializing new technology. In this podcast, Dennis Wahr discusses Nuvaira’s fund-raising success and what it means for its future (could an IPO be possible?) He also gives tips to other companies presenting at the May 17 Respiratory Innovation Summit in Dallas, another Healthegy-organized event. AttendRIS.com